Cellectis SA, of Paris, said the Institut Pasteur was awarded U.S. Patent Nos. 6,528,313 and 6,528,314 related to the homologous recombination process. Cellectis, the patents' licensee, said they cover specific replacement of a copy of a gene present in the recipient genome by the integration of a gene different from that where the integration is made.

Nabi Biopharmaceuticals, of Boca Raton, Fla., was issued U.S. Patent No. 6,537,559 titled "Staphylococcus aureus antigen-containing whole cell vaccine." The patent covers the composition of an S. aureus vaccine, the method of vaccine preparation, immunotherapy and its use as a therapeutic or prophylactic agent.

New York Health Care Inc., of Brooklyn, N.Y., said its wholly owned subsidiary, Bio Balance Corp., was issued a U.S. patent covering a nonpathogenic probiotic microorganism, its formulation and processes of manufacturing. It also covers the formulation of the invention for its probiotic/therapeutic uses.

Norwood Abbey Ltd., of Melbourne, Australia, was issued U.S. Patent No. 6,532,387 titled "Catheter for Delivering Electromagnetic Energy for Enhanced Permeation of Substances." The patent describes multi-lumen catheter devices capable of delivering high concentrations of pharmaceutically active substances and varying types of electro-magnetic energy to a selected site.

OxiGene Inc., of Watertown, Mass., was awarded U.S. Patent No. 6,538,038 titled "Compositions and Methods for Use in Vascular Targeting Destruction." It covers the use of multiple vascular targeting agents to treat cancer, macular degeneration and other illnesses characterized by the formation of abnormal blood vessels.

Pacific Biometrics Inc., of Seattle, was granted U.S. Patent No. 6,531,300 titled "Target Amplification of Nucleic Acid with Mutant RNA Polymerase." Acquired in a recent asset purchase transaction with Saigene Corp., also of Seattle, Pacific Biometrics said the patent could play a role in its efforts to develop molecular technologies.

Peregrine Pharmaceuticals Inc., of Tustin, Calif., said the University of Southern California in Los Angeles was issued U.S. Patent No. 6,524,823 covering liposomal conjugates that act to increase tumor blood vessel permeability. Exclusively licensed to Peregrine, the patent covers methods for selectively delivering liposomes to tumors that act to increase vascular permeability and expand blood volume at or in proximity to the tumor site.

Targeted Genetics Corp., of Seattle, received U.S. Patent No. 6,537,540 titled "Methods and Compositions for Lowering the Level of Tumor Necrosis Factor (TNF) in TNF-Associated Disorders." It covers both intramuscular and intravenous routes of delivery of a TNF antagonist to lower levels of, and treat symptoms related to, elevated levels of the inflammatory cytokine associated with several inflammatory diseases.

Transkaryotic Therapies Inc., of Cambridge, Mass., was issued U.S. Patent No. 6,531,124 titled "In Vivo Production and Delivery of Insulinotropin for Gene Therapy," and U.S. Patent No. 6,537,542 titled "Targeted Introduction of DNA into Primary or Secondary Cells and Their Use for Gene Therapy and Protein Production." The former relates to gene therapy for the delivery of glucagon-like peptide 1 (GLP-1) in treating diabetes, and the latter relates to gene targeting or the insertion of DNA into a precise location within the cell's genome, and methods for producing such homologously recombinant cells.

Warren Pharmaceuticals Inc., of Ossining, N.Y., was issued U.S. Patent No. 6,531,121 titled "Protection and Enhancement of Erythropoietin-Responsive Cells, Tissues and Organs." It relates to the use of WP-170, a chemical derivative of a hematopoetic cytokine, to protect or maintain the viability of responsive cells, tissues and organs under a wide variety of normal and adverse conditions.